iCo Therapeutics Subsidiary to present Oral Amphotericin B / | The Kingston Whig Standard
Article content Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium – Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsore...
Source: thewhig.com